Longevity & AgingDr. Brad Stanfield Explains Why He Chooses Low-Dose Tirzepatide Daily
Dr. Brad Stanfield outlines why he personally takes low-dose tirzepatide, a dual GLP-1/GIP receptor agonist, over newer options like retatrutide. Beyond weight loss, he covers accumulating clinical evidence showing GLP-1 medications reduce cardiovascular events, slow kidney disease progression, may inhibit obesity-related cancer progression, and show surprising benefits for osteoarthritis — including direct cartilage effects beyond weight loss alone. He also discusses metabolic liver disease (MASH), alcohol use disorder signals, and key safety considerations including pancreatitis and thyroid cancer risks. For health-optimizing adults, this video offers a practical, evidence-grounded framework for evaluating GLP-1 therapy as a multi-system longevity tool rather than simply a weight loss drug.
